ClinicalTrials.gg
CompletedNCT02141282Updated Dec 19, 2022Results posted

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

A Phase 2 interventional study of Venetoclax in Chronic Lymphocytic Leukemia, sponsored by AbbVie. Completed at 15 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2022-12-19.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
127
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell — 21 open to participants now, 42 under way, 8 of them phase 3. venetoclax · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
22nd of 69
127 · median 72
Started
2014
with 5 others
Phase 2
41 of 69
16 open now
Registered
7th of 69
by date
Lead sponsor
11 of 69
AbbVie

Among the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 22nd largest by enrollment, is one of 6 that started in 2014, is one of 41 in phase 2, and was the 7th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

21 of the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This was an open-label, non-randomized, multicenter, Phase 2 study evaluating the efficacy and safety of ABT-199 in 127 participants with relapsed or refractory chronic lymphocytic leukemia (CLL) after B-cell receptor signaling pathway inhibitors (BCR PI) treatment.

03

Conditions studied

  • Chronic Lymphocytic Leukemia

Keywords

  • Oncology
  • Chronic Lymphocytic Leukemia
  • Cancer of the blood and bone marrow
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have a diagnosis of chronic lymphocytic leukemia (CLL) that meets 2008 Modified International Workshop on Chronic Lymphocytic Leukemia National Cancer Institute-Working Group (IWCLL NCI-WG) criteria
  • Participant has disease with an indication for treatment
  • Participant has refractory disease or developed recurrence after therapy with a B-cell receptor pathway inhibitor (BCR PI)
  • Participant must have an performance score of ≤ 2
  • Participant must have adequate bone marrow function at Screening
  • Participant must have adequate coagulation profile, renal, and hepatic function, per laboratory reference range at Screening

Exclusion criteria

Exclusion Criteria:

  • Participant has undergone an stem cell transplant within the past year
  • Participant has developed Richter's transformation confirmed by
  • Participant has active and uncontrolled cytopenia
  • Participant has malabsorption syndrome or other condition that precludes enteral route of administration
  • Participant is (HIV) positive or has chronic or virus requiring treatment
  • Participant has known or allergy to both xanthine oxidase inhibitors and rasburicase
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    ABT-199 after ibrutinib therapy

    Participants with ibrutinib-resistant or refractory chronic lymphocytic leukemia (CLL) received venetoclax tablets once daily (QD) until disease progression or study drug discontinuation; median time on treatment was 593 days. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.

    Drug: Venetoclax

  • Experimental
    ABT-199 after idelalisib therapy

    Participants with idelalisib-resistant or refractory chronic lymphocytic leukemia (CLL) received venetoclax tablets once daily (QD) until disease progression or study drug discontinuation; median time on treatment was 1023 days. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.

    Drug: Venetoclax

  • Experimental
    ABT-199 after ibrutinib therapy: Expansion Cohort

    Participants with ibrutinib-resistant or refractory chronic lymphocytic leukemia (CLL) received venetoclax tablets once daily (QD) until disease progression or study drug discontinuation; median time on treatment was 622 days. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg. Participants enrolled into the Expansion Cohort with bulky disease at study entry who were non-responders or those who showed signs of clinical progression after completing the ramp up to 400 mg either by clinical disease assessment or by CT/MRI scan between Week 6 to Week 12 may have been permitted to escalate venetoclax to a daily dose of 600 mg.

    Drug: Venetoclax

  • Experimental
    ABT-199 after idelalisib therapy: Expansion Cohort

    Participants with idelalisib-resistant or refractory chronic lymphocytic leukemia (CLL) received venetoclax tablets once daily (QD) until disease progression or study drug discontinuation; median time on treatment was 1189 days. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg. Participants enrolled into the Expansion Cohort with bulky disease at study entry who were non-responders or those who showed signs of clinical progression after completing the ramp up to 400 mg either by clinical disease assessment or by CT/MRI scan between Week 6 to Week 12 may have been permitted to escalate venetoclax to a daily dose of 600 mg.

    Drug: Venetoclax

Interventions

  • Each dose of venetoclax was to be taken with approximately 240 mL of water within 30 minutes after the completion of breakfast or the participant's first meal of the day.

    Also known as: ABT-199, VENCLEXTA®

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Overall response rate is defined as the percentage of participants with an overall response (per the investigator assessment) 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL) National Cancer Institute-Working Group (NCI-WG) criteria.

    Time frame: At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort

Secondary outcomes

  1. Duration of Response (DOR)

    DOR is defined as the number of days from the date of first response (complete response \[CR\], complete response with incomplete marrow recovery \[CRi\], nodular partial remission \[nPR\], or partial remission \[PR\]) to the earliest recurrence or progressive disease. DOR was analyzed by Kaplan-Meier (K-M) methodology.

    Time frame: At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort

  2. Time to Progression (TTP)

    TTP is defined as the number of days from the date of first dose to the date of earliest disease progression (PD). TTP was analyzed by Kaplan-Meier (K-M) methodology.

    Time frame: At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort

  3. Progression-free Survival (PFS)

    PFS is defined as the number of days from the date of first dose to the date of earliest disease progression (PD) or death. PFS was analyzed by Kaplan-Meier methodology.

    Time frame: At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort

  4. Overall Survival (OS)

    OS is defined as the number of days from the date of first dose to the date of death for all dosed participants. For participants who did not die, their data was censored at the date of last study visit or the last known date to be alive, whichever was later. OS was estimated using Kaplan-Meier methodology.

    Time frame: At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort

Other outcomes

  1. Time to Next Anti-Chronic Lymphocytic Leukemia Treatment (TNNT)

    TNNT is defined as the number of days from the date of the first dose of venetoclax to the date of first dose of any non-protocol anti-leukemia therapy (NPT) or death from any cause. For participants who did not take NPT, their data was censored at the last known date to be free of NPT. TTNT was analyzed by Kaplan-Meier methodology.

    Time frame: Collected every 3 months for a period of 5 years after the last participant had enrolled into the study

  2. Percentage of Participants With Minimal Residual Disease (MRD) Negativity Status

    The rate of MRD response is defined as the percentage of participants who had MRD negative status.

    Time frame: Assessed at Week 24, Day 1; after the first Complete Response, Complete Remission with Incomplete Marrow Recovery, or Partial Response; at 12-week interval visits until two consecutive negative MRD levels were reported

07

Results

Posted Dec 19, 2022

Participant flow

Participant flow — Overall Study
MilestoneABT-199 After Ibrutinib TherapyABT-199 After Idelalisib TherapyABT-199 After Ibrutinib Therapy: Expansion CohortABT-199 After Idelalisib Therapy: Expansion Cohort
Started43214815
Completed0000
Not completed43214815
Withdrew: Adverse event, not related to progression8131
Withdrew: Adverse event, related to progression1020
Withdrew: Covid-19 infection1000
Withdrew: Lost to follow-up0042
Withdrew: Other, not specified1411239
Withdrew: Progressive disease, richter's4111
Withdrew: Progressive disease per protocol12792
Withdrew: Stem cell transplant1010
Withdrew: Study terminated by sponsor0100
Withdrew: Subject non-compliance0010
Withdrew: Withdrew consent2040

Outcome measures

PrimaryOverall Response Rate (ORR)

Overall response rate is defined as the percentage of participants with an overall response (per the investigator assessment) 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL) National Cancer Institute-Working Group (NCI-WG) criteria.

Time frame:
At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsABT-199 After Ibrutinib Therapy: Main and Expansion CohortsABT-199 After Idelalisib Therapy: Main and Expansion Cohorts
Overall Response Rate (ORR)64.8 (54.1 to 74.6)69.4 (51.9 to 83.7)
SecondaryDuration of Response (DOR)

DOR is defined as the number of days from the date of first response (complete response \[CR\], complete response with incomplete marrow recovery \[CRi\], nodular partial remission \[nPR\], or partial remission \[PR\]) to the earliest recurrence or progressive disease. DOR was analyzed by Kaplan-Meier (K-M) methodology.

Time frame:
At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort
Reported as:
Median · months
Duration of Response (DOR)
monthsABT-199 After Ibrutinib Therapy: Main and Expansion CohortsABT-199 After Idelalisib Therapy: Main and Expansion Cohorts
Duration of Response (DOR)35.1 (19.4 to 50.5)55.4 (32.0 to NA)
SecondaryTime to Progression (TTP)

TTP is defined as the number of days from the date of first dose to the date of earliest disease progression (PD). TTP was analyzed by Kaplan-Meier (K-M) methodology.

Time frame:
At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort
Reported as:
Median · months
Time to Progression (TTP)
monthsABT-199 After Ibrutinib Therapy: Main and Expansion CohortsABT-199 After Idelalisib Therapy: Main and Expansion Cohorts
Time to Progression (TTP)36.1 (21.9 to 49.0)43.4 (20.1 to NA)
SecondaryProgression-free Survival (PFS)

PFS is defined as the number of days from the date of first dose to the date of earliest disease progression (PD) or death. PFS was analyzed by Kaplan-Meier methodology.

Time frame:
At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort
Reported as:
Median · months
Progression-free Survival (PFS)
monthsABT-199 After Ibrutinib Therapy: Main and Expansion CohortsABT-199 After Idelalisib Therapy: Main and Expansion Cohorts
Progression-free Survival (PFS)24.7 (19.2 to 40.9)43.4 (20.1 to NA)
SecondaryOverall Survival (OS)

OS is defined as the number of days from the date of first dose to the date of death for all dosed participants. For participants who did not die, their data was censored at the date of last study visit or the last known date to be alive, whichever was later. OS was estimated using Kaplan-Meier methodology.

Time frame:
At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort
Reported as:
Median · months
Overall Survival (OS)
monthsABT-199 After Ibrutinib Therapy: Main and Expansion CohortsABT-199 After Idelalisib Therapy: Main and Expansion Cohorts
Overall Survival (OS)69.6 (51.3 to NA)NA (57.2 to NA)
Other pre-specifiedTime to Next Anti-Chronic Lymphocytic Leukemia Treatment (TNNT)

TNNT is defined as the number of days from the date of the first dose of venetoclax to the date of first dose of any non-protocol anti-leukemia therapy (NPT) or death from any cause. For participants who did not take NPT, their data was censored at the last known date to be free of NPT. TTNT was analyzed by Kaplan-Meier methodology.

Time frame:
Collected every 3 months for a period of 5 years after the last participant had enrolled into the study
Reported as:
Median · months
Time to Next Anti-Chronic Lymphocytic Leukemia Treatment (TNNT)
monthsABT-199 After Ibrutinib Therapy: Main and Expansion CohortsABT-199 After Idelalisib Therapy: Main and Expansion Cohorts
Time to Next Anti-Chronic Lymphocytic Leukemia Treatment (TNNT)24.0 (18.7 to 40.9)37.8 (17.1 to NA)
Other pre-specifiedPercentage of Participants With Minimal Residual Disease (MRD) Negativity Status

The rate of MRD response is defined as the percentage of participants who had MRD negative status.

Time frame:
Assessed at Week 24, Day 1; after the first Complete Response, Complete Remission with Incomplete Marrow Recovery, or Partial Response; at 12-week interval visits until two consecutive negative MRD levels were reported
Reported as:
Number · percentage of participants
Percentage of Participants With Minimal Residual Disease (MRD) Negativity Status
percentage of participantsABT-199 After Ibrutinib Therapy: Main and Expansion CohortsABT-199 After Idelalisib Therapy: Main and Expansion Cohorts
Peripheral blood30.8 (21.5 to 41.3)25.0 (12.1 to 42.2)
Bone marrow6.6 (2.5 to 13.8)11.1 (3.1 to 26.1)

Adverse events

Collected over All-cause mortality reported from enrollment to 30 d after last dose of study drug; median time on follow up was up to 1694 d for those with ibrutinib-resistant or refractory CLL and up to 1942 d for those with idelalisib-resistant or refractory CLL. TEAEs and SAEs collected from first dose of study drug until 30 d after last dose of study drug; mean duration on study drug was 819.8 d (ibrutinib-resistant or refractory CLL cohorts) and 1151.5 d (idelalisib-resistant or refractory CLL cohorts).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABT-199 After Ibrutinib Therapy: Main Cohort25/43 (58.1%)35/43 (81.4%)43/43 (100%)
ABT-199 After Idelalisib Therapy: Main Cohort9/21 (42.9%)14/21 (66.7%)21/21 (100%)
ABT-199 After Ibrutinib or Idelalisib Therapy: Main Cohort34/64 (53.1%)49/64 (76.6%)64/64 (100%)
ABT-199 After Ibrutinib Therapy: Expansion Cohort17/48 (35.4%)26/48 (54.2%)48/48 (100%)
ABT-199 After Idelalisib Therapy: Expansion Cohort4/15 (26.7%)9/15 (60%)15/15 (100%)
ABT-199 After Ibrutinib or Idelalisib Therapy: Expansion Cohort21/63 (33.3%)35/63 (55.6%)63/63 (100%)
ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts42/91 (46.2%)61/91 (67%)91/91 (100%)
ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts13/36 (36.1%)23/36 (63.9%)36/36 (100%)
All Participants55/127 (43.3%)84/127 (66.1%)127/127 (100%)
Most frequent serious events
Showing 10 of 124
Most frequent serious events
EventABT-199 After Ibrutinib Therapy: Main CohortABT-199 After Idelalisib Therapy: Main CohortABT-199 After Ibrutinib or Idelalisib Therapy: Main CohortABT-199 After Ibrutinib Therapy: Expansion CohortABT-199 After Idelalisib Therapy: Expansion CohortABT-199 After Ibrutinib or Idelalisib Therapy: Expansion CohortABT-199 After Ibrutinib Therapy: Main and Expansion CohortsABT-199 After Idelalisib Therapy: Main and Expansion CohortsAll Participants
FEBRILE NEUTROPENIABlood and lymphatic system disorders10/431/2111/643/480/153/6313/911/3614/127
PNEUMONIAInfections and infestations6/433/219/643/481/154/639/914/3613/127
SEPSISInfections and infestations0/430/210/641/482/153/631/912/363/127
PYREXIAGeneral disorders0/432/212/642/481/153/632/913/365/127
INFLUENZAInfections and infestations0/432/212/640/480/150/630/912/362/127
ANAEMIABlood and lymphatic system disorders0/430/210/641/481/152/631/911/362/127
ATRIAL FLUTTERCardiac disorders0/430/210/640/481/151/630/911/361/127
CARDIAC FAILURE CONGESTIVECardiac disorders0/430/210/640/481/151/630/911/361/127
CHEST PAINGeneral disorders0/430/210/641/481/152/631/911/362/127
MULTIPLE ORGAN DYSFUNCTION SYNDROMEGeneral disorders1/431/212/640/481/151/631/912/363/127
Most frequent other events
Showing 10 of 117
Most frequent other events
EventABT-199 After Ibrutinib Therapy: Main CohortABT-199 After Idelalisib Therapy: Main CohortABT-199 After Ibrutinib or Idelalisib Therapy: Main CohortABT-199 After Ibrutinib Therapy: Expansion CohortABT-199 After Idelalisib Therapy: Expansion CohortABT-199 After Ibrutinib or Idelalisib Therapy: Expansion CohortABT-199 After Ibrutinib Therapy: Main and Expansion CohortsABT-199 After Idelalisib Therapy: Main and Expansion CohortsAll Participants
NAUSEAGastrointestinal disorders24/436/2130/6430/484/1534/6354/9110/3664/127
NEUTROPENIABlood and lymphatic system disorders16/4310/2126/6420/489/1529/6336/9119/3655/127
ANAEMIABlood and lymphatic system disorders24/434/2128/6421/483/1524/6345/917/3652/127
DIARRHOEAGastrointestinal disorders22/439/2131/6426/488/1534/6348/9117/3665/127
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations15/439/2124/6419/487/1526/6334/9116/3650/127
FATIGUEGeneral disorders20/437/2127/6422/483/1525/6342/9110/3652/127
NEUTROPHIL COUNT DECREASEDInvestigations20/431/2121/6412/482/1514/6332/913/3635/127
PLATELET COUNT DECREASEDInvestigations19/431/2120/6411/484/1515/6330/915/3635/127
WHITE BLOOD CELL COUNT DECREASEDInvestigations18/432/2120/6416/483/1519/6334/915/3639/127
OEDEMA PERIPHERALGeneral disorders8/436/2114/6418/481/1519/6326/917/3633/127

Baseline characteristics

All treated participants

Age, Continuous
Age, Continuous(years)ABT-199 After Ibrutinib TherapyABT-199 After Idelalisib TherapyABT-199 After Ibrutinib Therapy: Expansion CohortABT-199 After Idelalisib Therapy: Expansion CohortTotal
Mean65.7 ± 8.7468.0 ± 7.2664.2 ± 10.7268.7 ± 8.3565.9 ± 9.34
Sex: Female, Male
Sex: Female, Male(Participants)ABT-199 After Ibrutinib TherapyABT-199 After Idelalisib TherapyABT-199 After Ibrutinib Therapy: Expansion CohortABT-199 After Idelalisib Therapy: Expansion CohortTotal
Female10617538
Male3315311089
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ABT-199 After Ibrutinib TherapyABT-199 After Idelalisib TherapyABT-199 After Ibrutinib Therapy: Expansion CohortABT-199 After Idelalisib Therapy: Expansion CohortTotal
White40194513117
Black22318
Asian10012
American Indian/Alaska native00000
Native Hawaiian or other Pacific Islander00000
Other00000
Multi race00000
08

Study locations

15 sites
  • Moores Cancer Center at UC San Diego /ID# 128535
    La Jolla, California 92093, United States
  • University of California, Los Angeles /ID# 127262
    Los Angeles, California 90095, United States
  • Stanford University School of Med /ID# 126495
    Stanford, California 94305-2200, United States
  • Georgetown University Hospital /ID# 127261
    Washington, District of Columbia 20007, United States
  • Emory Midtown Infectious Disease Clinic /ID# 131249
    Atlanta, Georgia 30322, United States
  • Northwestern University Feinberg School of Medicine /ID# 126497
    Chicago, Illinois 60611-2927, United States
  • Beth Israel Deaconess Medical Center /ID# 134509
    Boston, Massachusetts 02215-5400, United States
  • Dana-Farber Cancer Institute /ID# 126496
    Boston, Massachusetts 02215, United States
  • Columbia Univ Medical Center /ID# 128536
    New York, New York 10032-3725, United States
  • New York Presbyterian Hospital Weill Cornell Medical Center /ID# 129648
    New York, New York 10032-3725, United States
  • Univ Rochester Med Ctr /ID# 130011
    Rochester, New York 14642, United States
  • The Ohio State University /ID# 127263
    Columbus, Ohio 43210, United States
  • University of Pennsylvania /ID# 126860
    Philadelphia, Pennsylvania 19104-5502, United States
  • University of Texas MD Anderson Cancer Center /ID# 126498
    Houston, Texas 77030, United States
  • University of Utah /ID# 130813
    Salt Lake City, Utah 84112-5500, United States
09

References and documents

Publications

  • Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 2019 Jul 11;134(2):111-122. doi: 10.1182/blood.2018882555. Epub 2019 Apr 25. PubMed 31023700 ↗
  • Coutre S, Choi M, Furman RR, Eradat H, Heffner L, Jones JA, Chyla B, Zhou L, Agarwal S, Waskiewicz T, Verdugo M, Humerickhouse RA, Potluri J, Wierda WG, Davids MS. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018 Apr 12;131(15):1704-1711. doi: 10.1182/blood-2017-06-788133. Epub 2018 Jan 5. PubMed 29305552 ↗
  • Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, Furman RR, Lamanna N, Barr PM, Zhou L, Chyla B, Salem AH, Verdugo M, Humerickhouse RA, Potluri J, Coutre S, Woyach J, Byrd JC. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 Jan;19(1):65-75. doi: 10.1016/S1470-2045(17)30909-9. Epub 2017 Dec 12. PubMed 29246803 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Dec 2021, 87 months.

Results were first posted in Dec 2022, 11 months after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 87 months is above that.

Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2014
First posted
May 19, 2014
StartActual
Sep 10, 2014
Primary completionActual
Dec 22, 2021
CompletionActual
Dec 22, 2021
Results first posted
Dec 19, 2022
Last update
Dec 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02141282
Lead sponsor
AbbVie
Collaborators
Roche-Genentech
Responsible party
Sponsor
First posted
May 19, 2014
Start date
Sep 10, 2014
Primary completion
Dec 22, 2021
Completion
Dec 22, 2021
Results posted
Dec 19, 2022
Last update
Dec 19, 2022

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion